Company Profile

Founded in Wuhan in 2011 by Chinese and French scientists,AtaGenix Laboratories Co., Ltd.serves as the R&D and production base for ProteoGenix in China. Covering a total area of 4,700 square meters, the facility includes an 800-square-meter GMP-grade cell room and a 100-square-meter sterile, endotoxin-free purification laboratory, with an equipment investment exceeding 20 million RMB. Recognized as the designated Antibody Discovery and Screening Public Service Platform by Wuhan National Bio-Industry Base, AtaGenix combines advanced technical capabilities with an international development strategy, focusing on the development of independent technology platforms for recombinant proteins, antibodies, diagnostic materials, and antibody drug discovery, while fostering strategic collaborations for downstream biopharmaceutical products.

The company is committed to life sciences and has established three comprehensive technical service platforms:

• Life Sciences Platform: Equipped with five mature and efficient protein expression systems (mammalian cells, E. coli, Bacillus subtilis, yeast, and insect cells), it offers protein expression, molecular construction, protein purification, structural analysis, recombinant antibody expression, mouse/rabbit monoclonal antibody production, and related testing services.
• Diagnostic Material Development Platform: With an open automated chemiluminescence platform, it shortens R&D cycles, reduces development costs and technical risks, and provides customers with a variety of diagnostic core material development services.
• Antibody Drug Discovery Platform: Utilizing Single B cell antibody discovery, hybridoma screening, and phage display technologies, the platform offers antibody screening services using proprietary phage libraries, including SARS-CoV-2-specific antibody libraries, camelid nanobody libraries, rabbit natural antibody libraries, and mouse natural antibody libraries. Additionally, it provides phage library construction and screening services for various species such as mouse, rabbit, chicken, pig, cat, and dog.

The company has also developed a wide range of related products, including recombinant proteins, antibodies, tool enzymes, drug reference antibodies, industrial enzymes, and diagnostic materials.

Currently, AtaGenix 's proprietary technologies include high-density mammalian cell expression systems, MHC-peptide complex expression technology, multimer directional expression technology, hybridoma mouse monoclonal antibody production, Single B cell antibody discovery, production-scale stable cell line construction, phage library construction and screening, as well as antibody engineering (antibody humanization, affinity maturation, bispecific antibody development, etc.). To date, the company has successfully delivered tens of thousands of commissioned R&D projects related to recombinant proteins and antibodies. Its clients and partners include top academic research institutions and pharmaceutical companies worldwide, and it has established collaborations with FIND (Foundation for Innovative New Diagnostics), BAYER Crop Science, BioBay, Guangzhou Respiratory Health Research Institute, and strategic partnerships with the Translational Medical Research Center of Qingdao University Affiliated Hospital, Suzhou Institute of Systems Medicine, and Guangzhou Regenerative Medicine and Health Guangdong Laboratory.